The Highwire with Del Bigtree - THE HPV VACCINE’S ‘CANCER-PROOF’ PROMISE THAT WASN’T STUDIED

Episode Date: December 9, 2025

A new wave of headlines claim the HPV vaccine “prevents cancer,” but a Cochrane Collaboration review behind those headlines never actually studied cancer outcomes. Jefferey exposes what the review really admits, the pharma-funded conflicts buried in the fine print, and the true natural history of HPV—revealing how clever marketing was spun into so-called “proof.”Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

I want to talk about proof because people watching again mainstream corporate media, they're seeing headlines like this. We're going to go vaccine heavy because this is the conversation in America right now as far as the public health. Scientists confirm HPV vaccine does prevent cancer. Another one, HPV vaccine slashes cervical cancer risk with minimal side effects major review fines. I want to unpack this because when we see these headlines, we think, wait a minute, we know some of the science here. We know how this vaccine was brought to market when we see headlines like this we have to start questioning this so in order to really unpack this study that we're being told is a major study we have to look at what HPV is

this is a human papillomavirus and we go to the national institutes of health their national cancer institute their own their own website i want to read this research has found that it can take 5 to 10 years for HPV infected cervical cells to develop into pre-cancers and about 20 years is to develop into cancer. So the research we're being told is saying that cancer that develops in 20 years, this HPV shot can stop it. It's going to end it. So let's go to this research. It's from the Cochrane Collaboration. We're told this is gold standard science. This is an independent research organization and they just look at the facts. So this is their headline here. This is the human papillin vaccination for prevention of cervical cancer. They looked at 60 studies.

It's a meta-analysis. And you go right into there, the first couple paragraphs, you read this in this study. The researchers say, the studies, the 60, were not of sufficient duration for cancers to develop. Oh, okay. Well, that's not what the headlines I just read said. They said, it stopped cervical cancer. But the researchers are, okay, I'll take them from where the word is. So with any research, as Secretary H.JS Kennedy said, we're going to try to eliminate conflicts of interest. Why? well because conflicts of interest skew research results we know that it's common sense yeah so now let's go into the paper again this is a cock and cockham collaboration let's look at their conflicts

of interest it says out of those 60 studies 44 studies were funded by vaccine developers at 73 uh the glaxosmith klein 25 studies murk 18 studies sonope pastor goes on and on in 48 trials that's 80 percent authors had conflicts of interest due to being affiliated with or employed by and owning stock or holding patents in the vaccine development or manufacturing company. Okay, well, there's a whole other side of the conversation that will say conflicts of interest have nothing to do with it. All right, great. So let's go to the actual results here for cervical cancer. In 15 to 25 year old females, there was a reduction in CIN 2 plus irrespective of HPV vaccine type, the researchers right after six years, moderate certainty, and a large

reduction in CIN 2 plus from vaccine match HPV types, After six years, again, moderate certainty. So what are they talking about there? CIM plus, CIN 2 plus, this is cervical intra-epithelial neuroplasia. These are abnormal cells. There's a grading system of these abnormal cells. And I can show you this image here. You have a normal cell, you have the membrane, and then you have CIN 1, 2, 3.

And then after all of those abnormal cell grades, you have invasive cervical cancer forming, 20 years, according to the NIH it could take to get those to form. Now, I want to bring people's attention to the HPV vaccine on trial. This was a book written by three great authors, 2018. Dell, you interviewed them when the book came out, and they wrote about this HPV vaccine, the safety of it, how it came to market, and really the HPV vaccine industry.

And there's an image from this book looking at these grading systems. Just give people an idea. So here's this image. You have normal cell. Next in line to the right there, you have HPV infection. 90% clear spontaneously. Only 10% go to the C-I-N. Okay, so let's go to C-I-N-1.

5%, only 5% of those now go to C-I-N-2 or three. So now go to C-I-N-2. So the 10% move on and go past HBV. The rest have cleared. Of the 10% remaining 95% of them clear it by the time they're in CIN-1. So now you're, I don't even know how to do that math, but like your tiny percentage is now moving forward.

And then of that tiny percentage moving into CIN2, go ahead. Yep, we have 50 to 60 percent spontaneously regressed. The body can't fight this. Wow. CIN 3, 30 to 50 percent of those progress in the cervical cancer. And you can see there, 0.18, 18 percent of infections are cervical cancer. And that is from that book. And so there's, so CIN1, typically most of those go away.

CIN 2 and 3, if those are found, it's an outpatient procedure. removal and there's screening that can be done for this is a pap smear and it's recommended every several year every few years for women to have and you go into the the numbers on pap smears and you can look at this this study right here each year more than 50 five zero million pap smears and these are just looking for these abnormal cells they look under a microscope are performed in the United States to screen for cervical cancer 50 million most of the abnormal cells found during a pap smear are the result of a cervical or vaginal infection and are not cancerous. Of the three million women with

abnormal paps tests each year, less than 1%, 13,240 cases will be diagnosed with cervical cancer. Let's do the math. More than 50 million pap smears, it says, but let's just say 50 million pap smears. Out of those, three million women have abnormal pap smears, and out of those, only 13,240 have actual cervical cancer. You do the math on that, that's 0.02%, into cervical cancer. Wow. So that's what we're talking about here. But the Cochrane collaboration will, the headlines being produced from that will say the shot eliminates cervical cancer, period, full stop. And I'm trying to show people here that there's a lot more to this story and a lot more to that study than we're actually seen.

So just to be clear, so I understand this, they've said that we've proven that the HBV vaccine is reducing the risk of cancer, it's proven, it's working, but they never went to cancer. It was still too short a period of time to do that. So they just said it's reducing CIN2, which already is now a minimal percentage of people that will even progress to that point and then progress onwards, 50 to 60 percent of them, of those will still spontaneously clear. They don't care about that. They're saying that that's the endpoint that matters to them, and therefore, HPV is going to stop cervical cancer. I mean, it's what we keep seeing over and over and over.

It's like three-card Monty, man. Follow the ball. It's a shell game, total and complete baloney and really sad that Cochran that was once since, you know, a stand-up institution that we've celebrated is now regressed in clearly another Pharmashil company. Unbelievable. Thank you.